{"id":64312,"date":"2026-04-30T14:36:39","date_gmt":"2026-04-30T06:36:39","guid":{"rendered":"https:\/\/flcube.com\/?p=64312"},"modified":"2026-04-30T14:36:40","modified_gmt":"2026-04-30T06:36:40","slug":"eccogene-files-hong-kong-ipo-prospectus-with-thr-%ce%b2-agonist-ecc4703-leading-metabolic-disease-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64312","title":{"rendered":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline"},"content":{"rendered":"\n<p><strong>Eccogene Inc.<\/strong>, a Sino-U.S. biotechnology company founded in 2018, has filed its <strong>prospectus for an initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>. The company&#8217;s integrated pipeline features <strong>three clinical-stage candidates<\/strong> and <strong>three preclinical programs<\/strong> targeting metabolic diseases, with its core asset <strong>ECC4703<\/strong>\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-amp-capital-markets-milestone\">Corporate &amp; Capital Markets Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Eccogene Inc. (Sino-U.S. biotech, founded 2018)<\/td><\/tr><tr><td><strong>IPO Filing<\/strong><\/td><td>Hong Kong Stock Exchange prospectus submitted<\/td><\/tr><tr><td><strong>Pipeline Stage<\/strong><\/td><td>3 clinical-stage + 3 preclinical programs<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Dual presence in China and United States<\/td><\/tr><tr><td><strong>Therapeutic Areas<\/strong><\/td><td>Metabolic dysfunction-associated steatohepatitis (MASH) and obesity\/overweight<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-stage-pipeline-overview\">Clinical-Stage Pipeline Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-core-asset-ecc4703\">Core Asset: ECC4703<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Self-discovered <strong>oral, small-molecule, liver-targeting THR-\u03b2 full agonist<\/strong><\/li>\n\n\n\n<li><strong>Development Paths<\/strong>:<\/li>\n\n\n\n<li>Monotherapy and combination with <strong>ECC0509<\/strong> (SSAO inhibitor) for <strong>MASH<\/strong><\/li>\n\n\n\n<li>Adjunctive therapy with <strong>semaglutide<\/strong> (approved GLP-1RA) for <strong>obesity\/overweight<\/strong><\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Oral administration differentiates from injectable GLP-1-based competitors<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-additional-clinical-candidates\">Additional Clinical Candidates<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ECC5004\/Elecoglipron<\/strong>: Clinical-stage candidate (specific indication not detailed in announcement)<\/li>\n\n\n\n<li><strong>ECC0509<\/strong>: <strong>Semicarbazide-sensitive amine oxidase (SSAO) inhibitor<\/strong> for MASH combination therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-programs\">Preclinical Programs<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Program<\/th><th>Target\/Mechanism<\/th><\/tr><\/thead><tbody><tr><td><strong>GIP Program<\/strong><\/td><td>Glucose-dependent insulinotropic polypeptide pathway<\/td><\/tr><tr><td><strong>Amylin Program<\/strong><\/td><td>Amylin receptor agonism for metabolic regulation<\/td><\/tr><tr><td><strong>UPA Program<\/strong><\/td><td>Single-molecule multi-agonist platform technology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>MASH Market Opportunity<\/strong><\/td><td>Estimated $35-40 billion global market by 2030; no approved therapies currently available<\/td><\/tr><tr><td><strong>Obesity Market Dynamics<\/strong><\/td><td>GLP-1 revolution creating demand for complementary oral agents to enhance efficacy or reduce injection burden<\/td><\/tr><tr><td><strong>THR-\u03b2 Competitive Set<\/strong><\/td><td>Competing with Madrigal&#8217;s resmetirom (approved for MASH) and Viking Therapeutics&#8217; VK2809<\/td><\/tr><tr><td><strong>Oral Differentiation<\/strong><\/td><td>ECC4703&#8217;s oral bioavailability addresses key limitation of current GLP-1-based obesity treatments<\/td><\/tr><tr><td><strong>Combination Strategy<\/strong><\/td><td>Synergistic approach with semaglutide leverages established commercial infrastructure while enhancing therapeutic outcomes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-investment-thesis\">Strategic Implications &amp; Investment Thesis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Market Advantage<\/strong>: Sino-U.S. structure enables access to both Chinese regulatory pathways and U.S. capital markets expertise<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Multiple shots on goal across metabolic disease spectrum reduces single-asset dependency risk<\/li>\n\n\n\n<li><strong>Commercial Readiness<\/strong>: MASH indication could achieve first-in-class or best-in-class positioning in rapidly emerging market<\/li>\n\n\n\n<li><strong>Partnership Potential<\/strong>: Adjunctive obesity program creates natural partnership opportunities with established GLP-1 manufacturers<\/li>\n\n\n\n<li><strong>IPO Timing<\/strong>: Strong investor appetite for metabolic disease assets following recent MASH approvals and obesity market expansion<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial potential. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive developments, and capital market conditions affecting IPO execution.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26042906032_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26042906032_c.\"><\/object><a id=\"wp-block-file--media-3bd1c529-572a-4c3c-9385-1445978012f6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26042906032_c.pdf\">sehk26042906032_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/sehk26042906032_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3bd1c529-572a-4c3c-9385-1445978012f6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64316,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1981,72,86],"class_list":["post-64312","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eccogene","tag-ipo","tag-obesity"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company&#039;s integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64312\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline\" \/>\n<meta property=\"og:description\" content=\"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company&#039;s integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64312\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:36:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:36:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline\",\"datePublished\":\"2026-04-30T06:36:39+00:00\",\"dateModified\":\"2026-04-30T06:36:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312\"},\"wordCount\":422,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3002.webp\",\"keywords\":[\"Eccogene\",\"IPO\",\"Obesity\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64312#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64312\",\"name\":\"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3002.webp\",\"datePublished\":\"2026-04-30T06:36:39+00:00\",\"dateModified\":\"2026-04-30T06:36:40+00:00\",\"description\":\"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company's integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64312\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/3002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64312#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company's integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64312","og_locale":"en_US","og_type":"article","og_title":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline","og_description":"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company's integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.","og_url":"https:\/\/flcube.com\/?p=64312","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:36:39+00:00","article_modified_time":"2026-04-30T06:36:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64312#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64312"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline","datePublished":"2026-04-30T06:36:39+00:00","dateModified":"2026-04-30T06:36:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64312"},"wordCount":422,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","keywords":["Eccogene","IPO","Obesity"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64312#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64312","url":"https:\/\/flcube.com\/?p=64312","name":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64312#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64312#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","datePublished":"2026-04-30T06:36:39+00:00","dateModified":"2026-04-30T06:36:40+00:00","description":"Eccogene Inc., a Sino-U.S. biotechnology company founded in 2018, has filed its prospectus for an initial public offering (IPO) on the Hong Kong Stock Exchange. The company's integrated pipeline features three clinical-stage candidates and three preclinical programs targeting metabolic diseases, with its core asset ECC4703\u2014an oral, liver-targeting thyroid hormone receptor-beta (THR-\u03b2) full agonist\u2014positioned for multiple high-value indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64312#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64312"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64312#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","width":1080,"height":608,"caption":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64312#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eccogene Files Hong Kong IPO Prospectus with THR-\u03b2 Agonist ECC4703 Leading Metabolic Disease Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/3002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64312"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64312\/revisions"}],"predecessor-version":[{"id":64317,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64312\/revisions\/64317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64316"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64312"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64312"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}